Exploratory clinical and immunological changes following Tixagevimab/Cilgavimab administration in immunodeficient patients with SARS-CoV-2-associated ME/CFS and persistent circulating spike protein

Immunology Letters · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles